Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of peritoneal carcinomatosis (PC). The objective was to evaluate the outcomes of cytoreductive surgery (CRS) and HIPEC in our center.
Method: In this retrospective study, data were collected from 43 patients with PC who underwent CRS-HIPEC since 2016, at Faghihi Hospital of Shiraz University of Medical Sciences. Outcomes were collected and analyzed. Analyses were conducted through SPSS 23. P-value < 0.05 was considered to be statistically significant.
Results: The mean age of the patients was 52.23 ± 11.82 years. The participants in the study analysis consisted of 36 female (83.7%) and seven male patients (16.3%). The most common primary tumor was ovarian cancer (62.8%). Completeness of the cytoreduction score of CC0/CC1 was obtained in 87.7% of the patients. The overall and 60-day postoperative mortality rates were 27.9% and 7%, respectively. The 1- and 3-year overall survivals respectively were 88% and 60%.
Conclusion: Our study supports that employing CRS and HIPEC for PC is feasible with acceptable morbidity in our center.